Tue, August 13, 2024

Geulah Livshits Maintained (TSHA) at Strong Buy and Held Target at $7 on, Aug 13th, 2024

Geulah Livshits of Chardan Capital, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy and Held Target at $7 on, Aug 13th, 2024.

Geulah has made no other calls on TSHA in the last 4 months.



There are 6 other peers that have a rating on TSHA. Out of the 6 peers that are also analyzing TSHA, 0 agree with Geulah's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Geulah


  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $6 on, Monday, August 12th, 2024
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $7 on, Monday, July 1st, 2024
  • Keith Tapper of "BMO Capital" Initiated at Buy and Held Target at $5 on, Thursday, June 27th, 2024
  • Kristen Kluska of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $7 on, Thursday, June 20th, 2024
  • Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $5 on, Thursday, June 20th, 2024
  • Eun Yang of "Jefferies" Initiated at Strong Buy with Increased Target to $8 on, Tuesday, May 14th, 2024